Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 26:12:135-142.
doi: 10.2147/BTT.S180846. eCollection 2018.

Two decades with omalizumab: what we still have to learn

Cristoforo Incorvaia  1 , Marina Mauro  2 , Elena Makri  1 , Gualtiero Leo  3 , Erminia Ridolo  4
Affiliations
Review

Two decades with omalizumab: what we still have to learn

Cristoforo Incorvaia et al. Biologics. .

Abstract

From its availability for clinical use nearly two decades ago for severe asthma, omalizumab has gained strong evidence of efficacy and safety in the treatment of severe asthma not controlled by standard-of-care therapy. It has been acknowledged by Global Initiative on Asthma guidelines as add-on therapy against severe uncontrolled asthma. Thanks to controlled trials supporting its efficacy, omalizumab has also been licensed for the treatment of chronic spontaneous urticaria. The optimal duration of treatment in either disease has not been established. Despite its high price, omalizumab appears to be cost-effective in severe uncontrolled asthma as well as in chronic urticaria. The literature suggests a wide range of applications for omalizumab in various disorders regardless of allergic or non-allergic pathophysiology.

Keywords: anti-IgE antibody; chronic spontaneous urticaria; cost-effectiveness; efficacy; omalizumab; safety; severe asthma.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623–2632. - PubMed
    1. Jardieu PM, Fick RB. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999;118(2–4):112–115. - PubMed
    1. Milgrom H, Fick RB, Su JQ, Jq S. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341(26):1966–1973. - PubMed
    1. Global Initiative for Asthma Report, Global strategy for Asthma Management and Prevention. [Accessed May 13, 2018]. Available from: https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-manage...
    1. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;19(2):CD003559. - PubMed

LinkOut - more resources